

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/810,793	03/26/2004	Zhijian J. Chen	MPI96-031CP1DV1CPACN2M 1019	
30405 7	590 05/12/2006		EXAMINER	
MILLENNIUM PHARMACEUTICALS, INC. 40 Landsdowne Street CAMBRIDGE, MA 02139			PATTERSON, CHARLES L JR	
			ART UNIT	PAPER NUMBER
			1652	4
		DATE MAILED: 05/12/2006		

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Office Action Summers	10/810,793	CHEN, ZHIJIAN J.				
Office Action Summary	Examiner	Art Unit				
	Charles L. Patterson, Jr.	1652				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1) Responsive to communication(s) filed on						
_	-· action is non-final.					
<i>;</i>		secution as to the merits is				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4)⊠ Claim(s) <u>7-19</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>7-19</u> is/are rejected.						
7) Claim(s) is/are objected to.						
	alastian requirement					
8) Claim(s) are subject to restriction and/or election requirement.						
Application Papers						
9) The specification is objected to by the Examiner.						
10)⊠ The drawing(s) filed on <u>25 March 2004</u> is/are: a)⊠ accepted or b)⊡ objected to by the Examiner.						
Applicant may not request that any objection to the o						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119		•				
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:						
	1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)						
1) Notice of References Cited (PTO-892)	4) Interview Summary	(PTO-413)				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da					
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	6) Other:	atent Application (PTO-152)				

Application/Control Number: 10/810,793

Art Unit: 1652

Applicant's election without traverse of Group I, claims 7-19 in the reply filed on 3/30/06 is acknowledged. All of the non-elected claims have been cancelled. Election was made without traverse in the reply filed on.

Claim 10 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 10 is confusing and indefinite in the recitation of "is an antigen-binding fragment is selected from...", which should apparently be "is an antigen-binding fragment and is selected from...", or some similar recitation.

Claim 9 is rejected under 35 U.S.C. 101 because the claimed invention is not supported by either a specific and substantial asserted utility or a well established utility.

The instant claim is drawn to an antibody the binds to a subunit the consists of "p31, p33,...and p85". The only mention of these enzyme fragments in the specification are apparently on page 14 and 20. These fragments are simply stated as being subunits of an approximate molecular weight of 31kDa, 32kDa, etc., with no further characterization of them. It is apparently not stated what particular portions are not is there stated a specific utility for them. Therefore, there it is maintained that there is no specific and substantial utility for the antibody binding to these fragments.

Claim 9 is also rejected under 35 U.S.C. 112, first paragraph. Specifically, since the claimed invention is not supported by either a specific and substantial asserted utility or a well established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention. In addition, the specification does not teach one of or-

Application/Control Number: 10/810,793

Art Unit: 1652

dinary skill in the art how to obtain these fragments since they do not teach exactly what the fragments are.

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 7-19 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

Claim 7 is drawn to "[a]n antibody...which binds to a kinase or subunit thereof..." This reads on any antibody whatsoever that binds to the kinase or a subunit of it under any conditions whatsoever, however briefly or non-specifically. The specification teaches on pages 67-71 an antibody that has specific binding affinity to the kinase. This would limit the antibody to one that bound to the enzyme or subunit specifically, i.e. to that in contrast to all other antigens. The instant claim should be changed to an antibody that specifically binds, or some similar recitation.

No art rejection is being made. It is maintained that the instant claims are of the same scope as the parent application, U.S. Patent 6,787,346.

Application/Control Number: 10/810,793

Art Unit: 1652

Applicant submitted 13 pages of prior citation. Several of these references were duplicated on different pages. Notation of this was made on the PTO-1449.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Charles L. Patterson, Jr., PhD, whose telephone number is 571-272-0936. The examiner can normally be reached on Monday - Friday from 7:30 to 4:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura Achutamurthy, can be reached on 571-272-0928. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Charles L. Patterson, Jr. Primary Examiner

Page 4

Art Unit 1652

Patterson May 8, 2006